Cannabigerol (CBG) is a non-psychoactive cannabinoid that plays an important role in the biochemistry of the cannabis plant. CBG acts as a chemical precursor to other cannabinoids such as THC and CBD. This conversion typically takes place 6-8 weeks in the flowering cycle. CBG is present only in trace amounts in most cannabis strains, however some hemp strains are specifically cultivated to generate higher yields of this cannabinoid.
CBG displays a multitude of potential health benefits including working as a neuroprotectant, having antioxidant properties, aiding with skin ailments as an antibacterial and antifungal agent, appetite stimulation, treatment of gastrointestinal disorders, inflammation reduction, shows promise in fighting cancer, and lowering intraocular pressure, which may benefit glaucoma patients.
CBG interacts with both the CB1 and CB2 receptors, acting as a possible inhibitor to the psychoactive effects of THC. CBG is also thought to boost anandamide, an endocannabinoid that naturally increases dopamine levels and responsible for regulating various health functions such as mood, sleep, and appetite. GABA uptake in the brain may be obstructed by CBG, making this cannabinoid a possible anti-anxiety agent and muscle relaxant. CBG may also block serotonin receptors, showing potential antidepressant traits.
CBG holds promise to be a key constituent in the overall medicinal benefits cannabis may provide. As cannabis research continues to rapidly evolve, CBG may emerge as one of the most therapeutically applicable and diverse cannabinoids to offer a wide range of possible remedies. Feel free to ask any of our knowledgeable patient consultants with any questions you may have.